TIAA CREF Investment Management LLC increased its stake in shares of Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) by 74.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 225,233 shares of the medical equipment provider’s stock after purchasing an additional 96,156 shares during the period. TIAA CREF Investment Management LLC owned 0.12% of Corindus Vascular Robotics worth $419,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp raised its position in shares of Corindus Vascular Robotics by 6.3% during the 1st quarter. Bank of New York Mellon Corp now owns 163,012 shares of the medical equipment provider’s stock worth $214,000 after purchasing an additional 9,684 shares during the last quarter. Rhumbline Advisers raised its position in shares of Corindus Vascular Robotics by 67.6% during the 2nd quarter. Rhumbline Advisers now owns 80,868 shares of the medical equipment provider’s stock worth $150,000 after purchasing an additional 32,608 shares during the last quarter. Teachers Advisors LLC raised its position in shares of Corindus Vascular Robotics by 184.7% during the 2nd quarter. Teachers Advisors LLC now owns 167,633 shares of the medical equipment provider’s stock worth $312,000 after purchasing an additional 108,745 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of Corindus Vascular Robotics by 240.4% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 285,900 shares of the medical equipment provider’s stock worth $375,000 after purchasing an additional 201,900 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Corindus Vascular Robotics by 73.3% during the 1st quarter. Geode Capital Management LLC now owns 673,488 shares of the medical equipment provider’s stock worth $882,000 after purchasing an additional 284,855 shares during the last quarter.

Shares of Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) opened at $0.94 on Tuesday. Corindus Vascular Robotics Inc has a 1-year low of $0.40 and a 1-year high of $2.25.

Corindus Vascular Robotics (NYSEAMERICAN:CVRS) last released its quarterly earnings data on Tuesday, November 7th. The medical equipment provider reported ($0.04) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. The company had revenue of $2.43 million during the quarter, compared to the consensus estimate of $3.60 million. Corindus Vascular Robotics had a negative net margin of 372.63% and a negative return on equity of 94.27%.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/21/corindus-vascular-robotics-inc-cvrs-shares-bought-by-tiaa-cref-investment-management-llc.html.

Several research firms recently weighed in on CVRS. Zacks Investment Research upgraded shares of Corindus Vascular Robotics from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research report on Tuesday, August 29th. BidaskClub upgraded shares of Corindus Vascular Robotics from a “sell” rating to a “hold” rating in a report on Friday, August 25th. ValuEngine upgraded shares of Corindus Vascular Robotics from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Finally, Cowen and Company set a $3.00 price objective on shares of Corindus Vascular Robotics and gave the company a “buy” rating in a report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating and three have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $2.33.

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.

Want to see what other hedge funds are holding CVRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS).

Institutional Ownership by Quarter for Corindus Vascular Robotics (NYSEAMERICAN:CVRS)

Receive News & Ratings for Corindus Vascular Robotics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc and related companies with MarketBeat.com's FREE daily email newsletter.